Targeting plasma kallikrein with a novel bicyclic peptide inhibitor alleviates diabetic retinopathy disease hallmarks in a preclinical rat model

Isabelle Etienne, Tine Van Bergen, Jean H.M. Feyen.

Targeting plasma kallikrein with a novel bicyclic peptide inhibitor alleviates diabetic retinopathy disease hallmarks in a preclinical rat model.